vs
Side-by-side financial comparison of Silexion Therapeutics Corp (SLXN) and Youxin Technology Ltd (YAAS). Click either name above to swap in a different company.
Silexion Therapeutics Corp is the larger business by last-quarter revenue ($70.0K vs $39.4K, roughly 1.8× Youxin Technology Ltd). Youxin Technology Ltd runs the higher net margin — -324.8% vs -6302.9%, a 5978.1% gap on every dollar of revenue.
Silexion Therapeutics Corp is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and immunological diseases. It serves North American and global healthcare markets, with R&D focused on novel biologic candidates addressing unmet patient medical needs.
Youxin Technology Ltd is a China-based automotive digital service provider. It operates used car trading platforms, offers new car sales support, auto financing referrals, and after-sales resource matching for consumers and auto industry participants across mainland China, focusing on optimizing vehicle transaction efficiency.
SLXN vs YAAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.0K | $39.4K |
| Net Profit | $-4.4M | $-127.9K |
| Gross Margin | — | 67.9% |
| Operating Margin | -6294.3% | — |
| Net Margin | -6302.9% | -324.8% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.50 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $70.0K | — | ||
| Q3 25 | $39.0K | — | ||
| Q2 25 | $44.0K | $39.4K | ||
| Q3 24 | $0 | — |
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.5M | $-127.9K | ||
| Q3 24 | $-11.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 67.9% | ||
| Q3 24 | — | — |
| Q4 25 | -6294.3% | — | ||
| Q3 25 | -8441.0% | — | ||
| Q2 25 | -5190.9% | — | ||
| Q3 24 | — | — |
| Q4 25 | -6302.9% | — | ||
| Q3 25 | -8364.1% | — | ||
| Q2 25 | -5688.6% | -324.8% | ||
| Q3 24 | — | — |
| Q4 25 | $1.50 | — | ||
| Q3 25 | $2.88 | — | ||
| Q2 25 | $4.32 | — | ||
| Q3 24 | $274.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6M | $-374.6K |
| Total Assets | $7.2M | $132.2K |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | — | ||
| Q3 25 | $9.2M | — | ||
| Q2 25 | $3.5M | — | ||
| Q3 24 | $2.0M | — |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $120.0K | $-374.6K | ||
| Q3 24 | $-4.6M | — |
| Q4 25 | $7.2M | — | ||
| Q3 25 | $11.6M | — | ||
| Q2 25 | $5.8M | $132.2K | ||
| Q3 24 | $3.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.0M | $-88.6K |
| Free Cash FlowOCF − Capex | $-3.0M | — |
| FCF MarginFCF / Revenue | -4311.4% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-2.5M | $-88.6K | ||
| Q3 24 | $-2.7M | — |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-2.5M | — | ||
| Q3 24 | $-2.7M | — |
| Q4 25 | -4311.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5700.0% | — | ||
| Q3 24 | — | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 2.3% | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
